PUBLISHER: Grand View Research | PRODUCT CODE: 1750810
PUBLISHER: Grand View Research | PRODUCT CODE: 1750810
The global pharmaceutical contract manufacturing and research services market size is anticipated to reach USD 395.23 billion by 2030 and is projected to grow at a CAGR of 6.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Pharmaceutical companies are increasingly leveraging CMOs and CDMOs to avoid substantial capital investments in infrastructure and navigate complex regulatory landscapes. This strategic move allows them to concentrate resources on core competencies like drug discovery and commercialization. The economies of scale achieved by specialized contract organizations further contribute to reduced production costs.
The escalating complexity of drug development, particularly in biologics, biosimilars, HPAPIs, and personalized medicine, necessitates the advanced capabilities and expertise readily available within contract service providers. These organizations often possess cutting-edge technologies such as continuous manufacturing and sophisticated handling systems, which prove vital for efficient and compliant production.
Global health trends, including the rising prevalence of chronic diseases and the demand for affordable generics and biosimilars following patent expirations, are also key growth drivers. The stringent and evolving regulatory environment, coupled with the imperative for faster market entry, incentivizes pharmaceutical companies to utilize the established expertise of CMOs and CDMOs. The strategic geographic shifts towards cost-competitive regions like Asia-Pacific and the emergence of integrated CRO-CDMO models offering comprehensive solutions underscore the dynamic growth of this market.